GuidelinePancreas2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
Guideline in Pancreas, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04104529 (Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department), which is not on this map. Cited by 158 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Who cites it
158 citing papers in PubMed, 3 syntheses or guidelines pooled it, 360 citations in OpenAlex.
- [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].Der Internist · 2020Pooled it
- Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.The oncologist · 2019Pooled it
- Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.JAMA oncology · 2019Pooled it
- Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.Pituitary · 2022Trial
- Efficacy ofCurrent oncology (Toronto, Ont.) · 2020Trial
- TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.The oncologist · 2019Trial
- Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.The oncologist · 2019Trial
- Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- Role of Interventional Oncology in the Management of Neuroendocrine Tumors: 2026 Update.Current oncology reports · 2026Review
- Personalizing Postoperative Surveillance: A Risk-Stratified Predictive Model for Recurrence of Gastrointestinal Neuroendocrine Neoplasms.Journal of gastrointestinal cancer · 2026Article
- Primary Biliary Neuroendocrine Tumors: A Systematic Review of Surgical Management, Oncologic Outcomes and Implications for Personalized Care.Journal of personalized medicine · 2026Review
- NETest2.0Cancers · 2026Article
- Article
- Diagnostic Challenge of Small Bowel Neuroendocrine Tumour Mimicking Biliary Disease: A Case Report.Cureus · 2026Article
- Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease.Cardio-oncology (London, England) · 2026Article
- Carcinoid Heart Disease: 17-Year Follow-Up of Right Heart Double Bioprosthetic Valve Replacement.JACC. Case reports · 2026Article
- Article
- The Clinical Impact of Patent Foramen Ovale in Patients With Carcinoid Heart Disease.JACC. Advances · 2026Article
- Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors - A single center study of 378 patients.Journal of neuroendocrinology · 2026Article
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 3 countries.
Funding
Abstract
There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patients with refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.